Kevin Quon
Insider ownership, small-cap, long-term horizon, dividend investing

Amyris: Can This Industrial Biotechnology Pioneer Still Thrive?

Renewable products company, Amyris (AMRS), once stood on the top pedestal of the ongoing revolution in industrial biotechnology. By applying its synthetic biology platform to convert sugar into a variety of molecules, the company was on the cutting edge of creating the chemical building blocks needed to replace a wide range of petroleum-sourced products. In using genetically modified yeast, Amyris quickly proved the feasibility of its tiny microbial factories.

Early on in its corporate history, Amyris was awarded a 5-year, $42.6 million grant from the Bill and Melinda Gates Foundation via OneWorld Health. The grant was used for research into the synthetic creation of artemisinic acid. Artemisinic acid serves as a precursor to the creation of...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details